Along this line, Torre et al. (2021) applied a CRISPR–Cas9 genetic screen in melanoma cells to identify factors involved in the regulation of cellular plasticity targeting their primed state and thereby allowing them to survive BRAF inhibition and to develop drug resistance. The gene discussed is BRAF; the disease is melanoma.